Medication-related osteonecrosis of the jaw (MRONJ) is a severe condition that can develop in persons who take antiresorptive agents such as bisphosphonates, Denosumab, or antiangiogenic therapies. Moreover, that is used to treat cancer or Osteoporosis. The primary goal is to identify the most compelling new treatment options to promote and fasten healing periods and review all approaches to managing patients with medication-related jaw osteonecrosis. To evaluate the advantage of using platelet-rich plasma or low-level laser in combination with surgery as new options in managing extraction sites or unhealed surgical wounds in patients taking medication-related osteonecrosis of the jaw. And trying to concentrate on the practical maneuvers s in the literature regarding the management of MRONJ in an attempt to set an algorithm for managing this condition. We performed a literature review. An electronic search was done in PubMed and google scholar using the keywords: medication-related osteonecrosis of the jaw, platelet-rich plasma, low-level laser therapy, hyperbaric oxygen therapy, and Teriparatide. Articles from 2005 to 2022 were included in the review. The management options were divided into conservative, surgical, and combination therapy. A specific treatment protocol to manage MRONJ is still missing. Over the years, several treatment options have been proposed, including; conservative management (antibiotics, analgesics, oral hygiene), a surgical procedure that includes (debridement, curettage, and resection) and modern options Like (platelet-rich plasma, low-level laser therapy, hyperbaric oxygen therapy, Teriparatide dug) combined with surgery or along. Early or low-grade MRONJ can be managed conservatively. In advanced or refractory medication-related osteonecrosis of the jaw (pathological fracture, percutaneous fistula), surgical treatment, at present, remains the only treatment option available, but using a combination of treatment options that we mentioned above with surgical procedure can promote and fasten treatment periods.